ScreenerHero

ALZ Alzinova AB (publ)

STO · SE · Healthcare · Biotechnology · alzinova.com
0.4150SEK+10.96%Mkt Cap: 8.30M $P/E: —

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment o…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap8.30M USD
Enterprise Value6.05M USD
Revenue (TTM)14.25K USD
Gross Profit2.54M USD
Net Income (TTM)-2.51M USD
Revenue/Share0.0010 SEK
Last Price0.4150 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.62
PEG—
EV/EBITDA—
EV/Revenue424.69
P/S524.77
P/B0.49
EPS (TTM)-0.21
EPS (Forward)-0.60
52W Range
0.36802% of range2.280
52W High2.280 SEK
52W Low0.3680 SEK
Profitability
Gross Margin100.00%
Oper. Margin-17980.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-21.54%
ROA-18.31%
Growth
Revenue Growth-56.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.25M USD
CapEx (TTM)2.54M USD
FCF Margin-23227.60%
FCF Yield-39.89%
Net Debt-1.20M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio2.11
Quick Ratio2.06
Book Value/Sh0.77 SEK
Cash/Share0.07 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.867 SEK
Upside (mean)+350.0%
Target Range1.700 SEK – 2.035 SEK
1.700+350.0% to mean2.035
# Analysts2
Ownership
Shares Out.209.07M
Float171.73M
Insiders24.93%
Institutions14.04%
Technical
SMA 500.7574 (-45.2%)
SMA 2000.6587 (-37.0%)
Beta1.24
S&P 52W Chg16.45%
Avg Vol (30d)2.89M
Avg Vol (10d)2.97M
Technical Indicators
RSI (14)35.9
MACD-0.0943
MACD Signal-0.1032
MACD Hist.+0.0090
BB Upper0.6844 SEK
BB Middle0.4487 SEK
BB Lower0.2131 SEK
BB Width105.00%
ATR (14)0.0583 SEK
Vol Ratio (20d)1.20x